Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.10.0.1
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Net sales $ 162,970 $ 144,613
Operating income 25,763 26,031
Costs recognized on sale of acquired inventory (935) (318)
Amortization of acquisition related intangible assets (14,313)  
Corporate general, selling, and administrative expenses (67,051) (58,289)
Operating Segments [Member]    
Operating income 57,150 53,488
Operating Segments [Member] | Protein Sciences [Member]    
Net sales 126,391 108,113
Operating income 54,614 46,209
Operating Segments [Member] | Diagnostics and Genomics [Member]    
Net sales 36,747 36,589
Operating income 2,536 7,279
Intersegment Eliminations [Member]    
Net sales (168) (89)
Segment Reconciling Items [Member]    
Costs recognized on sale of acquired inventory (935) (318)
Amortization of acquisition related intangible assets (14,276) (11,379)
Acquisition related expenses (2,631) (9,533)
Stock-based compensation (11,565) (3,795)
Corporate, Non-Segment [Member]    
Corporate general, selling, and administrative expenses $ (1,980) $ (2,432)